|Bid||66.51 x 3100|
|Ask||66.79 x 1100|
|Day's range||66.13 - 66.86|
|52-week range||53.63 - 71.70|
|Beta (5Y monthly)||0.10|
|PE ratio (TTM)||122.81|
|Forward dividend & yield||1.44 (2.15%)|
|Ex-dividend date||24 Feb 2022|
|1y target est||72.70|
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
WILMINGTON, Del., August 16, 2022--AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).